Fa Liu

Fa Liu has over 17 years of experience in the pharmaceutical industry. From 2004 to 2009, Fa Liu worked at the National Cancer Institute (NCI) as a Staff Scientist and Visiting Fellow. During this time, Fa Liu discovered a set of highly-potent peptidomimetic inhibitors targeting Polo Box Domain of Polo-Like Kinase 1 as potential first-in-class anti-cancer agents. From 2009 to 2014, Fa Liu worked at Eli Lilly and Company as a Senior Research Scientist and Research Scientist. During this time, Fa Liu was involved in peptide drug discovery involving multiple therapeutic areas and delivered one clinical candidate molecule. From 2014 to 2015, Fa Liu worked at Calibrium, LLC as the Director of Chemistry, where they were involved in the discovery and early development of novel peptide therapeutics for the treatment of metabolic diseases. From 2015 to 2016, Fa Liu worked at Indiana University Bloomington as an Adjunct Professor, Department of Chemistry, where they co-mentored graduate students and postdoc scientists. From 2016 to 2020, Fa Liu worked at Novo Nordisk as the Head of Discovery Chemistry and Director of Chemistry. From 2020 to 2022, Fa Liu worked at Focus-X Therapeutics, Inc. as the President, Co-founder and CEO, where they focused on the discovery and early development of novel radionuclide-drug conjugates fulfilling unmet needs in solid tumor treatment. In November 2022, Focus-X Therapeutics, Inc. was acquired by Full-Life Technologies, where Fa Liu currently serves as the Chief Scientific Officer.

Fa Liu completed their B.S. in Chemistry from Nankai University between 1995 and 1999. Fa then went on to earn their Ph.D. in Organic Chemistry from Shanghai Institute of Organic Chemistry between 1999 and 2004.